Security key
M47238148
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD)
CUSIP: M47238148
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Ordinary Shares, NIS 1.80 par value per share
- Total 13F shares
- 44,767
- Total 13F value
- $142,806
- Share change
- +39,167
- SEC-reported price per share
- $3.19
- Number of holders
- 11
- Value change
- +$124,943
- Number of buys
- 4
- Number of sells
- 1
- Shares outstanding
- 5,591,387
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
11
Top holders
10
GLMD full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2025
Previous quarter: Q3 2024
Galmed Pharmaceuticals Ltd. SEC filings
Galmed Pharmaceuticals Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M47238148
Recent filing periods:
Ownership snapshot
Top reported holders of GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Allen Baharaff
Disclosed value leader
Allen Baharaff
Comparable rows
10/10
Latest evidence
31 Dec 2024
13D/G
13F
Lead comparable stake: 2.6%
13D/G row: Allen Baharaff
Showing 1-6 of 10 holder rows.
Quick read
Allen Baharaff leads the comparable SEC ownership view at 2.6%.
10 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Allen Baharaff's linked filing trail.
Comparable ownership
Top 5
Allen Baharaff
2.6%
UBS Group AG
0.09%
Tower Research Capital LLC (TRC)
0%
MORGAN STANLEY
0%
WELLS FARGO & COMPANY/MN
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Allen Baharaff |
13D/G
|
2.6%
|
$60,455
44,128 shares
|
$0 | 31 Dec 2024 |
| UBS Group AG |
13F
Company
|
0.09%
|
$36,132
5,267 shares
|
— | 30 Sep 2024 |
| Tower Research Capital LLC (TRC) |
13F
Company
|
0%
|
$1,187
173 shares
|
— | 30 Sep 2024 |
| MORGAN STANLEY |
13F
Company
|
0%
|
$713
104 shares
|
— | 30 Sep 2024 |
| WELLS FARGO & COMPANY/MN |
13F
Company
|
0%
|
$123
18 shares
|
— | 30 Sep 2024 |
| Federation Des Caisses Desjardins du Quebec |
13F
Individual
|
0%
|
$96
14 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
11
Shares
44,767
Rows available
11
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
9
Q4 2024 holders
11
Holder diff
2
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend